Skip to main content
. 2020 Jun 4;38(24):2728–2740. doi: 10.1200/JCO.19.02760

FIG 3.

FIG 3.

Cumulative incidence of subsequent neoplasms by mutation (mut) status of DNA repair genes and treatment exposures. (A) Subsequent female breast cancer by mutation status of homologous recombination (HR) genes and dose of chest radiotherapy (RT). (B) Subsequent female breast cancer by mutation status of HR genes and dose of anthracyclines. (C) Subsequent sarcoma by mutation status of HR genes and dose of alkylating agents. (D) Subsequent thyroid cancer by mutation status of nucleotide excision repair (NER) genes and dose of neck RT. The cumulative incidence curves are statistically different (P < .001) in all 4 panels. Additional statistical tests between group pairs and across the 3 groups except Group 1 (blue line) are included in the Data Supplement. A similar set of cumulative incidence curves with years since diagnosis as the x-axis is provided in the Data Supplement.